Osteosarcoma News and Research

RSS
Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with approximately 1,200 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group (COG), the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
Volvo Cars and ALSF support families affected by pediatric cancer

Volvo Cars and ALSF support families affected by pediatric cancer

A potentially better option to blocks tumors

A potentially better option to blocks tumors

Better health and prosperity in Europe via improved clinical research

Better health and prosperity in Europe via improved clinical research

Immune-based therapy approved in Europe for pediatric cancer patients

Immune-based therapy approved in Europe for pediatric cancer patients

UK survival for children's bone cancer lowest in Western Europe

UK survival for children's bone cancer lowest in Western Europe

Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteosarcoma

Epeius Biotechnologies announces results of Rexin-G in chem-resistant metastatic soft tissue sarcoma and osteosarcoma

Paving the way for future pan-European clinical trials

Paving the way for future pan-European clinical trials

Early stage drug shows promise against cancer cells from young patients

Early stage drug shows promise against cancer cells from young patients

IDM Pharma receives not approvable letter for Mifamurtide for treatment of osteosarcoma

IDM Pharma receives not approvable letter for Mifamurtide for treatment of osteosarcoma

Rapamycin study is first stage in development of new treatment

Rapamycin study is first stage in development of new treatment

CTRC enrolls first patients in study for sarcoma

CTRC enrolls first patients in study for sarcoma

IDM Pharma plans to amend NDA for Mifamurtide (L-MTP-PE) for the treatment of osteosarcoma

IDM Pharma plans to amend NDA for Mifamurtide (L-MTP-PE) for the treatment of osteosarcoma

Curing canine cancer - human cancer benefit

Curing canine cancer - human cancer benefit

Childhood sarcoma increases risk of blood clots

Childhood sarcoma increases risk of blood clots

Oncolytics Biotech to proceed with phase II Sarcoma trial

Oncolytics Biotech to proceed with phase II Sarcoma trial

Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma

Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma

Fewer deaths from cancer in the U.S.

Fewer deaths from cancer in the U.S.

No alarm on fluoride: cancer risk unproven

No alarm on fluoride: cancer risk unproven

Children with bone cancer in their arms or legs survival rate improved

Children with bone cancer in their arms or legs survival rate improved

Stem cells may cause some forms of bone cancer

Stem cells may cause some forms of bone cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.